ReviewCureus2022
Gold Nanoparticles in Cancer Therapeutics and Diagnostics.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- Metallic nanoparticles: from biosynthesis to biomedical applications, current scenarios and prospects.Nanoscale advances · 2026Review
- ADMET Profiling of the Metallodrugs: A Comparative Review of Platinum, Palladium, Gold, Ruthenium, Copper, and Zinc Anticancer Complexes.Bioinorganic chemistry and applications · 2026Review
- Influence of biopolymer based gold nanoparticles and photobiomodulation in in vitro wound healing.Scientific reports · 2025Article
- Multifunctional nanoplatforms based on RNA interference for glioma treatment.American journal of cancer research · 2025Review
- Nanotherapeutic and Nano-Bio Interface for Regeneration and Healing.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional treatment for cancer is done by chemotherapy, radiotherapy, and/or surgery, which work by inhibiting the growth of the rapidly dividing neoplastic cells and excision of the neoplastic tissue, respectively. These methods affect the healthy tissues along with the diseased ones, as chemotherapeutic agents often cause toxicity in the body and a variety of unfavorable side effects, which can highly impair bodily functions. Otherwise, while operating, there is the danger of some cancerous cells not being excised or unnecessary additional removal of healthy tissues, again causing the patient to lose some functionality of their body. The emerging field of nanotechnology helps to revolutionize imaging and therapeutic management in cancer. The use of metallic nanoparticles, especially those derived from an inert metal like gold, which has a great list of advantages such as high biocompatibility, non-toxicity, easy synthesis, and effective functionality, makes this innovative technology crucial for further propagation of this field. These nanoparticles have a dual function, i.e., helping in precise fluorescent bioimaging and drug delivery of potent medication to specific tissue sites without affecting the general area highly in a negative fashion. Thus, integrating these methods into current clinical practice would advance our methods for diagnostics as well as treatment while decreasing the stress on the patient, overall elevating medical practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.